Multiple sclerosis (MS) is an autoimmune demyelinating condition that mainly affects young adults worldwide. Despite the advances in MS research, the autoantigen(s) that causes this condition remains to be elucidated. Robinson et al. in their seminal 2003 Nature Medicine paper utilized the reverse proteomics approach of identifying complex autoantibodies from human and mouse (EAE) samples. They developed a protein array to identify autoantigens and validated these targets in the EAE model. This paper relays critical understanding related to MS pathogenesis at multiple levels; it utilizes cutting-edge technology and bioinformatics tools to identify disease signature(s) in MS with the aim of developing tolerizing therapy in autoimmune diseases including MS.
Suggested by May Han
Multiple sclerosis (MS) is an autoimmune demyelinating condition that mainly affects young adults worldwide. Despite the advances in MS research, the autoantigen(s) that causes this condition remains to be elucidated. Robinson et al. in their seminal 2003 Nature Medicine paper utilized the reverse proteomics approach of identifying complex autoantibodies from human and mouse (EAE) samples. They developed a protein array to identify autoantigens and validated these targets in the EAE model. This paper relays critical understanding related to MS pathogenesis at multiple levels; it utilizes cutting-edge technology and bioinformatics tools to identify disease signature(s) in MS with the aim of developing tolerizing therapy in autoimmune diseases including MS.